Positive Phase III data point to new option for anemia in kidney disease

8 November 2021

GlaxoSmithKline (LSE: GSK) has announced positive results from the Phase III ASCEND trial of its investigational anemia drug, daprodustat.

Data from the study of the oral HIF-PH inhibitor was presented during the American Society of Nephrology’s Kidney Week 2021.

GSK’s results show the study met its primary efficacy endpoint, with strong safety data confirming the potential for daprodustat to be a new option for people with anemia due to chronic kidney disease, in both non-dialysis and dialysis settings.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK